SEC Form 4 · accession 0001209191-17-031690
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martha J Demski
Director
Period of report
May 11, 2017
Accepted (ET)
May 11, 2017 · 8:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.15 | May 11, 2017 | A | 63,500 | A | — | May 11, 2027 | Common Stock | 63,500 | 63,500 | D |
Explanation of responses
- F1Option shares vest and become exercisable in twelve (12) equal monthly installments measured from the vesting commencement date, February 15, 2017, with full acceleration of the option shares upon the event of a change in control.